34017-27-1

Usage

Uses

Used in Dietary Supplements:
S-METHYL-L-CYSTEINE METHYL ESTER HYDROCHLORIDE is used as a dietary supplement for its potential antioxidant and anti-inflammatory properties, aiming to support overall health by combating oxidative stress and inflammation.
Used in Liver Health Applications:
In the field of liver health, S-METHYL-L-CYSTEINE METHYL ESTER HYDROCHLORIDE is used as a protective agent to improve liver function and shield against liver damage, due to its potential to mitigate the effects of oxidative stress and inflammation on liver cells.
Used in Medical Research:
S-METHYL-L-CYSTEINE METHYL ESTER HYDROCHLORIDE is utilized as a subject of research in the medical field for its potential role in treating cardiovascular disease, diabetes, and cancer. Its antioxidant and anti-inflammatory properties are being investigated for their possible therapeutic effects on these conditions.

InChI:InChI=1/C5H11NO2S.ClH/c1-8-5(7)4(6)3-9-2;/h4H,3,6H2,1-2H3;1H/t4-;/m0./s1

Upstream product

• 67-56-1 methanol 
• 52-90-4 L-Cysteine 
• 1187-84-4 S-methyl-L-cysteine 
• 2485-62-3 L-Cysteine methyl ester 
• 616-38-6 carbonic acid dimethyl ester 
• 18598-63-5 L-cysteine methyl ester hydrochloride 
• 74-88-4 methyl iodide 
• 82835-08-3 methyl (R)-2-(tert-butoxycarbonylamino)-3-methylthiopropanoate 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 96792-80-2 N-Hippuroyl-S-methyl-L-cystein-methylester 
• 69977-56-6 (R)-2-amino-3-(methylthio)propan-1-ol 
• 97435-45-5 (R)-2-(2-Benzyloxycarbonylamino-acetylamino)-3-methylsulfanyl-propionic acid methyl ester 
• 76646-28-1 N-<(Benzyloxy)carbonyl>-S-methyl-L-cysteine Methyl Ester 
• 168648-46-2 (R)-2-amino-1,1-diphenyl-3-methylthio-1-propanol 
• 1011484-02-8 N-[(1R)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-S-methyl-L-cysteine 
• 1011484-01-7 N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-S-methyl-L-cysteine 
• 1290538-26-9 (R)-methyl 2-(2,4-dimethoxybenzylamino)-3-(methylthio)propanoate 
• 1415903-68-2 (S)-Ph₂PfcCONHCH(CH₂SMe)CO₂Me 
• 1187-84-4 S-methyl-L-cysteine 
• 17445-53-3 Carbobenzoxy-D-Phe-(S-methyl)-Cys 
• 17461-77-7 Carbobenzoxy-Phe-(S-methyl)-Cys 
• 77826-55-2 N,N'-bis(tert-butoxy)carbonyl-L-cystine dimethyl ester 

Relevant academic research and scientific papers

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer

A series of novel dipeptidyl boronic acid compounds were designed, synthesized and biologically investigated for the inhibition of the β5 subunit of 20S proteasome and several compounds showed high activities with IC50 values of less than 10 nM. Some of these compounds potently inhibited the multiple myeloma (MM) cancer cell lines with IC50 values of less than 10 nM. It was reported that the inhibition of both β2 and β5 subunits strongly increased the cytotoxicity of proteasome inhibitors in solid tumor cells, so some of the compounds were evaluated for the inhibition of the β2 subunit and the solid tumor triple-negative breast cancer cell line MDA-MB-231. The results showed that three compounds were active for both the β2 subunit and the triple-negative breast cancer cell line MDA-MB-231. The in vivo pharmacokinetic results showed that compound 8t had good biological parameters for both ig and iv administrations. An in vivo pharmacodynamic experiment showed that compound 8t inhibited the β5 subunit in whole blood more greatly than the marketed MLN9708 with the same dose at different time periods. A pathological analysis indicated that the injection of compound 8t in the tumor of a triple-negative breast cancer xenograft mice model led to tumor cell necrosis, nucleus condensation, deep staining, cell fragmentation, dissolution and neutrophil infiltration compared with the control group. The data in hand showed that compound 8t might be an effective candidate for the treatment of both MM and triple-negative breast cancer.

Synthesis and application of peptide borate compounds

The invention belongs to the field of drug synthesis, and specifically relates to a series of novel peptide borate compounds or pharmaceutical salts thereof, and a preparation method and pharmaceutical application thereof. The structure of the peptide borate compounds or the pharmaceutical salts thereof is as shown in a formula I which is described in the specification. The compounds of the invention can be used for preparing proteasome inhibitors, and thus can be further used for treating solid tumors and blood tumors.

Non-classical N-metallated Pd(II) pincer complexes featuring amino acid pendant arms: Synthesis and biological activity

A series of non-classical pincer ligands with the secondary amide central unit and amino acid pendant arms was obtained from 2-diphenylphosphanyl- and 2-methylsulfanylbenzoic acids and a range of amino acid derivatives (S-methyl-L-cysteine, L-methionine, and L-histidine methyl esters). In addition, the reactions of amino acid-functionalized chloroacetamides with in situ generated Ph2PSK afforded their counterparts with an aliphatic ligand backbone. All the compounds obtained smoothly underwent direct cyclopalladation upon interaction with PdCl2(NCPh)2 under mild reaction conditions, resulting in N-metallated pincer complexes with 5,6- and 6,6-membered fused metallocycles. The realization of κ3-S,N,S-, S,N,N- and S,N,P-coordination was unambiguously confirmed based on the IR and NMR spectroscopic data. In the case of the methionine-based thiophosphorylacetamide derivative, the unexpected selectivity in the formation of one complex diastereomer was observed in solution. The solid-state structures of some of the complexes obtained were also elucidated by X-ray crystallography. The preliminary investigations on cytotoxicity of the resulting palladocycles against HCT116, MCF7, and PC3 human cancer cell lines as well as HEK293 normal cells gave some insight into the structure–activity relationships for this relatively new type of potential anticancer agents. Some of the complexes demonstrated promising cytotoxic effects.

Dipeptide boric acid composed of carboxylic acid and alpha-amino acid as well as ester compound thereof, and preparation method and application of dipeptide boric acid and ester compound thereof

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

Bio-inspired nitrile hydration by peptidic ligands based on L-cysteine, L-methionine or L-penicillamine and pyridine-2,6-dicarboxylic acid

Nitrile hydratase (NHase, EC 4.2.1.84) is a metalloenzyme which catalyses the conversion of nitriles to amides. The high efficiency and broad substrate range of NHase have led to the successful application of this enzyme as a biocatalyst in the industrial syntheses of acrylamide and nicotinamide and in the bioremediation of nitrile waste. Crystal structures of both cobalt(III)- and iron(III)-dependent NHases reveal an unusual metal binding motif made up from six sequential amino acids and comprising two amide nitrogens from the peptide backbone and three cysteine-derived sulfur ligands, each at a different oxidation state (thiolate, sulfenate and sulfinate). Based on the active site geometry revealed by these crystal structures, we have designed a series of small-molecule ligands which integrate essential features of the NHase metal binding motif into a readily accessible peptide environment. We report the synthesis of ligands based on a pyridine-2,6-dicarboxylic acid scaffold and L-cysteine, L- S-methylcysteine, L-methionine or L-penicillamine. These ligands have been combined with cobalt(III) and iron(III) and tested as catalysts for biomimetic nitrile hydration. The highest levels of activity are observed with the L-penicillamine ligand which, in combination with cobalt(III), converts acetonitrile to acetamide at 1.25 turnovers and benzonitrile to benzamide at 1.20 turnovers.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES

The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited

Synthesis and evaluation of new endomorphin analogues modified at the Pro2 residue

Six new endomorphin analogues, incorporating constrained amino acids in place of native proline have been synthesized. Residues of (S)-azetidine-2-carboxylic acid (Aze), 3,4-dehydro-(S)-proline (Δ3Pro), azetidine-3-carboxylic acid (3Aze) and de

PRODRUGS OF INHIBITORS OF CATHEPSIN S

The present invention provides compounds of formula (I) which are prodrugs of inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstruct

Mild and highly chemoselective oxidation of thioethers mediated by Sc(OTf)3

(Matrix presented) Catalytic Sc(OTf)3 greatly increases the efficiency of hydrogen peroxide mediated monooxidation of alkyl-aryl sulfides and methyl cysteine containing peptides. The method is high yielding, compatible with many widely used protecting groups, suitable for solid-phase applications and proceeds with minimum over-oxidation.